|
Ä¿¸®¾îÄɾî |
´Ù±¹Àû Á¦¾àȸ»ç _ Á¾º´¿µ¾÷´ã´ç(2³â~4³â)
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
2³â¡è |
ä¿ë½Ã |
02.13 |
|
|
(ÁÖ)ÇÇÇÃÄɾî½áÄ¡ |
¢º RA(Regulatory Affairs), ÀÇ·á±â±â ÇØ¿Ü ÀÎÇã°¡( RA)¾÷¹«
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
°æ·Â¹«°ü |
ä¿ë½Ã |
07.14 |
|
|
ÄÚ¸®¾Æºê·¹ÀÎ ((ÁÖ)¿¡ÀÌÄ¡¾ËÇãºê) |
[¿Ü±¹°è ȸ»ç] Regulatory Affairs °æ·ÂÁ÷ (»ç¿ø/´ë¸®±Þ)
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
2³â¡è |
ä¿ë½Ã |
01.02 |
|
|
¾ÆÀ̺ñÄÁ¼³Æà |
BD(»ç¾÷°³¹ß, °³¹ß±âȹ) °£ºÎ»ç¿ø ¸ðÁý
¼¿ï ±¸·Î±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÇìµåÇåÅÍ |
10³â¡è |
ä¿ë½Ã |
06.04 |
|
|
ÄÚ¸®¾Æºê·¹ÀÎ ((ÁÖ)¿¡ÀÌÄ¡¾ËÇãºê) |
ÀÇ·á±â ÀÇ·áÁ¦Ç° º´¿ø¿µ¾÷´ã´ç
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
3³â¡è |
ä¿ë½Ã |
10.01 |
|
|
(ÁÖ)Ä¿¸®¾îºôµå |
R&D Research - ¿Ü±¹°è ±â¾÷
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
3³â¡è |
ä¿ë½Ã |
07.03 |
|
|
¹Ý¼®½áÄ¡(ÁÖ) |
(´ë±â¾÷ Á¦¾àȸ»ç) OTC ¸¶ÄÉÆÃ/PM (´ë¸®-ºÎÀå±Þ
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
5³â¡è |
ä¿ë½Ã |
09.09 |
|
|
ºñÀü¼Ä¡ |
ÄÚ½º´Ú µî·Ï ±Û·Î¹ú ¹ÙÀÌ¿À Á¦¾à»ç ÀÓ»ó°³¹ßÆÀÀå ¸ðÁý
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
8³â¡è |
ä¿ë½Ã |
11.14 |
|
|
ÄÚ¸®¾Æºê·¹ÀÎ ((ÁÖ)¿¡ÀÌÄ¡¾ËÇãºê) |
Medical Sales ´ë¸® - °úÀå
¼¿ï ¸¶Æ÷±¸, ºÎ»ê ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
1³â¡è |
ä¿ë½Ã |
01.07 |
|
|
(ÁÖ)ÀâÀ§µå |
[¿ÜÀÚÁ¦¾à/°³²¿ª] Àӻ󿬱¸ Coordinator(CRA)ä¿ë
¼¿ï ÀüÁö¿ª | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
09.22 |
|
|
ÁÖ½Äȸ»ç ÀÎÅÚ¸®Àü½ºÄÚ¸®¾Æ |
[¿Ü±¹°èÁ¦¾à»ç] CRA
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
5³â¡è |
ä¿ë½Ã |
07.07 |
|
|
(ÁÖ)ÀâÀ§µå |
[¿Ü±¹°èÁ¦¾à/»ï¼ºµ¿] CRA ä¿ë
¼¿ï °³²±¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
10.03 |
|
|
(ÁÖ)ÄھƼġ |
marketing specialist
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
4³â¡è |
ä¿ë½Ã |
07.21 |
|
|
(ÁÖ)ÄھƼġ |
QA Specialist
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
3³â¡è |
ä¿ë½Ã |
07.21 |
|
|
(ÁÖ)¸®¿ÂÆÄÆ®³Ê½º |
Country Head, Manager, Sr./Jr. cra ±Û·Î¹ú Pharm/cro(ÀçÅÃ
¼¿ï °³²±¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
12.01 |
|